Vatinoxan hydrochloride structure
|
Common Name | Vatinoxan hydrochloride | ||
|---|---|---|---|---|
| CAS Number | 130466-38-5 | Molecular Weight | 454.97100 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C20H27ClN4O4S | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of Vatinoxan hydrochlorideVatinoxan hydrochloride (MK-467 hydrochloride;L-659066 hydrochloride) is a peripheral α2 adrenergic receptor antagonist. |
| Name | N-[2-[(2R,12bS)-2'-oxospiro[1,3,4,6,7,12b-hexahydro-[1]benzofuro[2,3-a]quinolizine-2,5'-imidazolidine]-1'-yl]ethyl]methanesulfonamide,hydrochloride |
|---|---|
| Synonym | More Synonyms |
| Description | Vatinoxan hydrochloride (MK-467 hydrochloride;L-659066 hydrochloride) is a peripheral α2 adrenergic receptor antagonist. |
|---|---|
| Related Catalog | |
| Target |
α2 adrenergic receptor[1] |
| In Vivo | Vatinoxan alone increases cardiac index and tissue oxygen delivery and has no deleterious adverse effects. Vatinoxan attenuates or prevents dexmedetomidine’s systemic hemodynamic effects in a dose-dependent manner when given simultaneously i.v. but has no effect on the pulmonary outcome in conscious dogs. A 50:1 dose ratio (Vatinoxan:dexmedetomidine) induces the least alterations in cardiovascular function[1]. Vatinoxan dose-dependently attenuates the bradycardia associated with dexmedetomidine, and shortens the sedative effect without altering its quality. Vatinoxan may be useful in attenuating reductions in heart rate in conscious catsadministered dexmedetomidine[2]. |
| Animal Admin | Dogs[1] Eight dogs receive either dexmedetomidine (10 μg/kg), Vatinoxan (250 μg/kg or dexmedetomidine (10 μg/kg) with increasing doses of Vatinoxan (250 μg/kg, 500 μg/kg and 750 μg/kg). Treatments are given intravenously (i.v.) in a randomized, crossover design with a 14-day ishout period. Systemic hemodynamics and arterial blood gas analyses are recorded at baseline and at intervals up to 90 min after drugs administration[1]. Cats[2] Cats are administered seven IV treatments are administered at least 2 weeks apart, consisting of dexmedetomidine 12.5 μg/kg (D12.5) and 25 μg/kg (D25), Vatinoxan 300 μg/kg (M300), and D25 combined with 75, 150, 300 and 600 μg/kg of Vatinoxan (D25M 75, D25M150, D25M300 and D25M600, respectively). Heart rates (HR) are recorded via telemetry and sedation assessed with a simple descriptive score and a visual analogue scale prior to treatments and at intervals until 8 hours thereafter[2]. |
| References |
| Molecular Formula | C20H27ClN4O4S |
|---|---|
| Molecular Weight | 454.97100 |
| Exact Mass | 454.14400 |
| PSA | 106.76000 |
| LogP | 3.22850 |
| InChIKey | UTMOWVIYZQWJHT-VASSOYJASA-N |
| SMILES | CS(=O)(=O)NCCN1C(=O)NCC12CCN1CCc3c(oc4ccccc34)C1C2.Cl |
| Storage condition | 2-8℃ |
| Vatinoxan hydrochloride |